29 Mar 2019 by AXXELIS
Roche technology measures Parkinson’s disease fluctuations
This is another fine example of how smartphones could be used to good effect in modern day medicine. Roche Pharma Research & Early Development (pRED) has developed a smartphone-based monitoring system for those with Parkinson’s disease (PD) that complements the traditional physician-led assessments with automated tests that continuously measure their symptom fluctuations. This could be the first time that such a technology has been used to measure disease and symptom severity in a medicine development program in Parkinson’s disease.
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response
Recent studies have revealed a role for macrophages and neutrophils in limiting chemotherapy efficacy; however, the mechanisms underlying the therapeutic benefit of myeloid-targeting agents in combination with chemotherapy are incompletely understood. Here, we show that targeting tumour-associated macrophages by colony-stimulating factor-1 receptor (CSF-1R) blockade in the K14cre;Cdh1F/F;Trp53F/Ftransgenic mouse model for breast cancer stimulates intratumoural type I interferon (IFN) signalling, which enhances the anticancer efficacy of platinum-based chemotherapeutics.